Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Effector mutations discovered by advanced molecular profiling of non-small cell lung cancer (NSCLC) have altered the paradigm for treating this fatal condition. The identification of epidermal growth factor receptor (EGFR) mutations, which are predictive markers for the response to tyrosine kinase inhibitors (TKIs), has improved the prognosis and treatment of non-small-cell lung cancer (NSCLC). After breast cancer, lung cancer is the cancer with the second-highest global incidence, and it is getting more and more common. Lung cancer is anticipated to account for 2.2 million new cases of cancer in 2020, or about 11.4% of all cancer cases worldwide. In 2020, lung cancer will be responsible for 1 in 8 fatalities. In 2004, a distinct and clinically significant molecular subset of lung cancer called non-small cell lung cancer (NSCLC) with EGFR mutations was identified. Both the basic sciences and the clinical community have studied this disease in great detail. level and has developed into a prototype for comprehending and managing oncogene-driven cancers.

Description

Effector mutations discovered by advanced molecular profiling of non-small cell lung cancer (NSCLC) have altered the paradigm for treating this fatal condition. Epidermal growth factor receptor (EGFR) mutations, which are predictive markers for the response to tyrosine kinase inhibitors (TKIs), have changed how non-small-cell lung cancer (NSCLC) is diagnosed and treated. The epidermal growth factor receptor (EGFR) gene mutations are the most prevalent "classic" mutations, and deletions in exon 19 and the point mutation L858R in exon 21 indicate a likelihood of resistance to tyrosine kinase inhibitors (TKIs) for the EGFR gene. Exon 20 insertions, exon 18-point mutations, and complex mutations make up the majority of "uncommon" EGFR mutations, which make up 10-18% of all EGFR mutations. Since EGFR-mutated patients with advanced NSCLC typically receive EGFR-TKIs as their first-line therapy, this molecularly mutated subtype of non-small cell lung cancer (NSCLC) is the most common. A primary resistance to EGFR-TKIs is present in 20-30% of these patients, though.

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) (Epidemiology)

Lung cancer is increasing in diagnoses globally, coming in second place to breast cancer. In 2020, there will be 2.2 million new cases of cancer, or 11.4% of all cancer cases worldwide. 1.8 million fatalities in 2020 will be caused by lung cancer. With North America and Europe having the highest incidence of the disease, lung cancer now has the highest mortality rate of any type of cancer worldwide. Depending on the region, there are significant regional variations in lung cancer incidence. The region with the highest incidence is Polynesia (37.3 per 100,000 people annually). West Africa has the lowest infection rate (2.2 per 100,000 people each year). As smoking rates rise in developing nations, particularly China and India, the incidence is expected to increase in the coming years. The global trend for lung cancer is decades behind that for smoking. Because fewer people smoke, lung cancer rates have decreased in many countries, including the US, Canada, the UK, and Australia. Lung cancer rates for men are still rising globally, despite the fact that they are beginning to level off in the United States. Chinese women are more susceptible to lung cancer than European women despite smoking rates being much lower in China. Most lung cancer cases occur in people between the ages of 50 and 70. Neither men nor women should expect to develop lung cancer at age 39. Following that, it began to gradually increase before reaching its peak among people over the age of 70. After the age of 40, lung cancer risk is still higher for men of all ages. Lung cancer tends to strike men more frequently than it does women. Men's lung cancer incidence has declined in the US as well as northern and western Europe. Lung cancer cases are rapidly increasing in Eastern and Southern European countries. The majority of Western countries are currently experiencing an alarming rise in the incidence of patients who are younger and more female. Women are typically younger when symptoms first appear, and they are more likely to present with adenocarcinoma and localized disease. Incidence of lung cancer among men and women aged 30 to 54 has decreased over the past 20 years in all racial and ethnic groups. However, there has been a significant decline in male incidence. As a result, young women have a higher risk of developing lung cancer than young men. For instance, among non-Hispanic whites and Hispanics aged 44 to 49 years, the female-to-male ratio for lung cancer increased from 0.88 in 1995-1999 to 1.17 in 2010-2014.

Advanced EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) -Current Market Size & Forecast Trends

The market for advanced EGFR-mutant non-small cell lung cancer (NSCLC) is projected to grow significantly, with estimates indicating a value of approximately USD 19.85 billion in 2023. This market is expected to reach around USD 66.20 billion by 2033, reflecting a compound annual growth rate (CAGR) of 12.8% during this period. The growth is driven by the increasing incidence of NSCLC, particularly among patients with EGFR mutations, and the development of next-generation targeted therapies, including EGFR tyrosine kinase inhibitors (TKIs) like osimertinib, which are expected to dominate the treatment landscape. The advanced EGFR-mutant NSCLC market is well-positioned for substantial growth through 2035 as new therapies and treatment strategies continue to emerge.

Tyrosine kinase inhibitors (TKIs) are more effective against tumors with EGFR mutations, but both primary and acquired resistance to these medications continues to be a significant clinical issue. A new era of non-small cell lung cancer (NSCLC) therapy has begun as a result of sensitizing mutations in the epidermal growth factor receptor (EGFR), which are related to a favorable response to EGFR-targeted therapy. Around 90% of NSCLC mutations are exon 19 deletions and exon 21 L858R substitutions, which are referred to as "classical mutations" and have a high sensitivity to tyrosine kinase inhibitors (TKIs) as a result. Other EGFR mutations include G719X, S768I, L861Q, exon 20 insertions, and less frequent EGFR mutations; complex mutations are the most prevalent type. Point mutations such as G719X, S768I, and L861Q are more susceptible to the effects of first-generation TKIs than those with complex mutations. When combined with second-generation TKIs, afatinib offered some patients with NSCLC a better prognosis than when used alone with first-generation TKIs, according to a prospective analysis. The conventional treatment for patients with exon 20 splicing is chemotherapy, but as new targeted agents are created, chemotherapy's function is changing. Additionally, there have been significant improvements in immunotherapy clinical trials that target uncommon EGFR mutations. Rare EGFR mutations in NSCLC patients are still being treated, and it's not clear how sensitive these mutations are to TKIs. Palliative care for patients with non-small cell lung cancer (NSCLC) with active EGFR mutations has increased with the approval of targeted therapies, specifically the first-generation tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. When compared to platinum-based chemotherapy, both drugs had improved therapeutic effects in phase III trials, including progression-free survival and tumor response without tumor response. The same is true for afatinib, an irreversible second-generation tyrosine kinase inhibitor (HER Pan inhibitor), which inhibits not only EGFR but also all members of the HER (or ErbB) family. Additionally, afatinib significantly increased overall survival in patients with common EGFR mutations, especially those with EGFR mutations, compared to double-platinum drugs, according to a pooled analysis of two-phase III studies (LUX-Lung 3 and 6). chemotherapy. Mutations in the EGFR gene are frequent. The first direct comparison of second- and first-generation TKIs was made in the LUX-Lung 7 study, which was published in 2016. In this phase II study, patients with NSCLC who shared active EGFR mutations were treated with afatinib or gefitinib in the primary care setting. Although the third primary endpoint, overall survival, was not achieved, afatinib significantly increased progression-free survival and time to treatment failure.

Report Highlights

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - Current Market Trends

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - Current & Forecasted Cases across the G8 Countries

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - Market Opportunities and Sales Potential for Agents

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - Patient-based Market Forecast to 2035

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - Untapped Business Opportunities

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - Product Positioning Vis-a-vis Competitors' Products

Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) - KOLs Insight